Overview

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

Status:
NOT_YET_RECRUITING
Trial end date:
2031-07-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of different adjuvant chemotherapy regimens for low-risk triple-negative breast cancer patients predicted by mRNA-lncRNA model
Phase:
PHASE3
Details
Lead Sponsor:
Fudan University
Treatments:
Cyclophosphamide
Docetaxel
Epirubicin
Paclitaxel